‘ENSURING DRUG SECURITY’ RUSSIAN PHARMACEUTICAL FORUM PROGRAMME

June 14 2023, St. Petersburg

Programme accurate as at June 20, 2023

June 14, 2023

10:00–11:30

Pavilion G
conference hall G4

‘Ensuring Drug Security’ Russian Pharmaceutical Forum

Orphan Diseases and Medicines: International Cooperation as a Tool to Improve Effectiveness and Access to Treatment

Patients with rare diseases around the world face significant challenges in ensuring early and accurate diagnosis and access to life-saving treatment. Orphan diseases place a heavy burden on the healthcare system due to the limited availability of pathogenic therapies and their high cost. The development of new drugs is a knowledge-intensive and costly process. The feasibility of investment in it by pharmaceutical companies depends on the size of the potential market. In addition, the limited number of patients makes it difficult to conduct full-scale clinical trials in one country. Cross-country collaboration at all stages of making treatment of patients with orphan diseasesavailable, from development, clinical trials, collection, and analysis of real-world clinical practice data to consolidation of demand for procurement, is of particular importance in this context. What strategies for ensuring the availability of orphan drugs are being implemented in the Russian Federation and in foreign countries? What approaches are most appropriate for molecular genetic research for orphan diseases? What solutions can contribute to the creation of rare disease patient registries? What obstacles do pharmaceutical companies encounter when introducing orphan drugs to the Russian and foreign markets? What approaches exist in Russian and international practice to increase the effectiveness of financing innovative orphan drugs? Should the experience of the Circle of Kindness Foundation be extended to the provision of drugs for adult patients? How to ensure the availability of unregistered orphan drugs? What platforms are needed to build a cross-country dialogue on drug development and improve the regulatory environment for market access?

Moderator:

- **Sergey Kutsev**, Director of the Federal State Budgetary Scientific Institution “Medical Genetic Research Center named after A.I. Academician N.P. Bochkov"; Chief Freelance Specialist in Medical Genetics of the Ministry of Health of Russia

Panellists:

- **Hesa Sabah Al Doseri**, Chief, Health Facilities Regulation, National Health Regulatory Authority of the Kingdom of Bahrain (NHRA)
- **Oleg Ergashev**, Vice-Governor of Saint Petersburg
- **Elena Maksimkina**, Director, "Federal Center for Planning and Regulation of Medical Supply Circulation" of the Ministry of Health of the Russian Federation
- **Inga Nizharadze**, General Director, Skopinfarm
- **Vitaliy Omelyanovskiy**, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
- **Aleksandr Rumyantsev**, Scientific Director, Dmitry Rogachev National Research Centre **(online)**
- **Aleksandr Tkachenko**, Archipiest; Chairman of the Committee of Charity and Social Work of the Civic Chamber of the Russian Federation; Chairman of the Board, Circle of Kindness

Foundation

- **Yury Zhulev**, President, Russian Hemophilia Society

Front row participants:

- **Darya Kryuchko**, Head of the Department of Translational Medicine and Innovative Technologies, Federal Medical and Biological Agency (FMBA of Russia)
- **Oleg Lapochkin**, Committee on Health Care and Health-Saving Technologies, Business Center for Economic Development of the CIS

10:00–11:30

Pavilion G
conference hall G5

'Ensuring Drug Security' Russian Pharmaceutical Forum

The Pharmaceutical Industry in Russia: Results of the Reset

During the period of 2020-22, the domestic pharmaceutical industry proved its responsibility and high level of expertise. The pandemic forced the industry to mobilize its resources and to quickly seek solutions in the face of unprecedented challenges. According to statistics from 2022, domestically manufactured medicines make up 82% of the 810 items identified as International Nonproprietary Names on the list of vital and essential drugs (VED), while more than 53% of the drugs have already gone through the full drug development process. The share of domestically produced drugs in government procurement is more than 80%; the production volume of medicines has increased by more than 10%, and the production of pharmaceutical substances has increased by more than 7%. A total of 940 new domestically manufactured medicines have been registered. The industry's achievements are, among other things, the result of joint work based on the implementation of the Pharma 2020 strategy. What trends and current challenges are included in the Pharma-2030 strategy, and is the Russian pharmaceutical industry ready to accept these challenges? What specific steps need to be taken to strengthen the domestic pharmaceutical industry on the threshold of the implementation of new plans? How ambitious and feasible are the stated objectives?

Moderator:

- **Aleksey Kedrin**, Chairman of the Board, Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (EAEU)

Panellists:

- **Sergey Glagolev**, Deputy Minister of Health of the Russian Federation
- **Dmitry Kudlay**, Vice President for the Implementation of New Medical Technologies, Generium
- **Timofey Nizhegorodtsev**, Deputy Head, Federal Antimonopoly Service of the Russian Federation **(online)**
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Lyudmila Scherbakova**, Co-Founder, Chairman of the Board of Directors, Velpharm
- **Aleksandr Semenov**, President, Active Component
- **Dmitry Zaitsev**, General Director, Pharmstandard

10:00–11:30

Pavilion G
conference hall G6

'Ensuring Drug Security' Russian Pharmaceutical Forum

Drug Provision for Cancer Patients

Government programmes for inpatient and outpatient drug provision for cancer patients enable full-scale care to be provided to patients. However, their availability and quality may vary from region to region. As oncology enters the era of personalization, the volume of molecular genetic tests is steadily increasing. According to oncology experts, the volume of molecular genetic, pathological, and anatomical studies is unevenly distributed at regional level each year. As far back as last year, it had

been proposed to update financing and the number of personalized diagnostics, taking into account morbidity, volume standards, and financial resources for pathological and molecular-genetic studies in view of analysis of execution in 2022 and define the minimum acceptable list of such studies taking into account clinical guidelines. This experience must be analyzed. Combination chemotherapy is gaining in relevance and use, which requires revision of clinical guidelines, additional clinical trials, and revision of clinical statistical groups. Is the level of supply of the required volume of drugs to cancer centres sufficient today? Are there interchangeability schemes for biosimilars and generic oncology drugs within treatment standards? To what extent are domestic manufacturers prepared to take on the necessary volume of supply?

Moderator:

- **Evelina Zakamskaya**, Chief Editor, Doctor TV Channel

Panellists:

- **Irina Borovova**, President, Association of Cancer Patients "Zdravstvuy!"
- **Evgeny Kamkin**, Deputy Minister of Health of the Russian Federation **(online)**
- **Andrey Kaprin**, General Director, Federal State Budgetary Institution National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Chief Freelance Specialist Oncologist of the Ministry of Health of the Russian Federation **(online)**
- **Diana Kobesova**, Deputy General Director for Pharmaceutical Business Development, Rusatom Healthcare
- **Galina Shemanaeva**, Acting Deputy Head of Administration of the Tambov Region
- **Yan Vlasov**, Co-Chairman, Russian Patient Association

10:00–11:30

Pavilion G
conference hall G7

'Ensuring Drug Security' Russian Pharmaceutical Forum

Import Substitution and Exports for the New Times: Solutions that Strengthen Local Players

The policy of import substitution was established back in the early stages of development of the domestic pharmaceutical industry. Today, in the context of global challenges, the issue of drug security is no longer a theory, but a modern Russian reality. The national pharmaceutical industry is faced with the task of developing timely strategies to respond to the current agenda, the highest priority requirements of which include ensuring continuity of supply of strategically important medicines and medical devices, achieving technological sovereignty for the industry, and maintaining competitiveness in foreign markets, which the biggest Russian manufacturers have successfully achieved. What are Russian companies preparing for today, what kind of strategies are they choosing, and to what extent do those tally with the government's demands? Is it possible to talk about trends in intensifying production cycles? What barriers currently stand in the way of achieving technological sovereignty? What measures can support the development of high-tech exports now that sanctions have been imposed? Are Russian producers ready to develop new markets and competences? What role do state corporations and large holding companies play in developing the production of materials, components, and raw materials?

Moderator:

- **Aleksandr Petrov**, Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Panellists:

- **Darya Borisova**, Member of the Board – Managing Director for Development and Innovations, SIBUR
- **Alexander Braverman**, First Deputy Chairman, VEB.RF

- **Victor Fisenko**, First Deputy Minister of Health of the Russian Federation **(online)**
- **Dmitriy Galkin**, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation
- **Danica Grujicic**, Minister of Health of the Republic of Serbia
- **Rajiv Kumar**, General Director, Raymed Trading Group
- **Evgeniya Shapiro**, Director General, PSK Pharma

Front row participant:

- **Vsevolod Belousov**, Director, "Federal Center of Brain Research and Neurotechnologies" of the Federal Medical Biological Agency

12:15–13:45

Pavilion G
conference hall G4

'Ensuring Drug Security' Russian Pharmaceutical Forum

Antibiotics and Safety: How Can Antibiotics Remain Effective?

Antibiotics were invented 95 years ago. World medicine has developed a unique opportunity to save lives and defeat deadly diseases in whole or in part. Today, however, antibiotics have become a cause for alarming debate in the medical expert community. Unrestricted use of antibiotics is becoming a global problem and could lead to a fatal reduction in their effectiveness against infectious diseases. To date, around 700,000 people worldwide die each year from infections caused by antibiotic-resistant pathogens. According to some experts, antibiotic resistance could cause 10 million deaths a year by 2050. Compounding the problem is the fact that the global drug market is experiencing a shortage of innovative new drugs to fight the most dangerous and resistant pathogens. What changes to the marketing and prescribing of antibiotics can reverse their overuse? How can control of the circulation of antibiotics in the pharmaceutical market be strengthened, while their production, distribution, and use more carefully regulated? Can epidemiological surveillance limit the uncontrolled use of antibiotics? Will the world be able to withstand the spread of antimicrobial resistance and how will it deal with future infectious diseases?

Moderator:

- **Olga Kobyakova**, Director, Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation

Panellists:

- **Renad Alyautdin**, Head of the Department for Expertise of the Safety of Medicines, Federal State Budgetary Institution "Scientific Center for Expertise of Medicinal Products" of the Ministry of Health of Russia
- **Oksana Drapkina**, Director, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
- **Roman Kozlov**, Chief Freelance Specialist of the Ministry of Health of the Russian Federation for Clinical Microbiology and Antimicrobial Resistance; President, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)
- **Yury Lobzin**, Children's Clinical Research Centre for Infectious Diseases, Federal Biomedical Agency
- **Yulia Mihaleva**, Deputy Director, Russian Quality System (Roskachestvo)
- **Alla Samoylova**, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)

12:15–13:45

Pavilion G
conference hall G5

'Ensuring Drug Security' Russian Pharmaceutical Forum

Strategy for Introducing Personalized Medicine

The causes and mechanisms of a whole range of complex multifactorial diseases such as cancer,

diabetes, Alzheimer's disease, and autoimmune and metabolic conditions are now known. Reductionist medicine, focused on identifying the 'main' cause of disease and the areas for therapeutic action, is a thing of the past. The precise mechanisms of the orchestration of events leading to pathologies and endogenous factors contributing to the progression of a disease are already known. The depth of this knowledge opens the door to precision medicine, in which it is possible to select treatment strategies based on the specific current mechanisms of how an illness develops, what course it takes, and the precise molecular profile. Moreover, by taking into account the physiology, environment, lifestyle factors and history of each individual patient, personalized approaches tailored to each patient are possible as part of precision medicine. This paradigm necessitates a change in the principles of clinical research: conducting it in small groups of differentiated patients with particular characteristics. What actions and decisions are required of industry participants – regulators, developers, manufacturers, doctors, and patients – in the practice of precision medicine? Is the pharmaceutical industry prepared to differentiate its approaches to the development and introduction of different drug combinations and different approaches to a single disease? How will the transition to personalized medicine expand the market for medicines and revitalize approaches to treatment?

Moderator:

- **Alexey Martynov**, President, Association of Biomedical Cellular Products Manufacturers

Panellists:

- **Alexey Belyaev**, Director, National Medical Research Center of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation
- **Danica Grujicic**, Minister of Health of the Republic of Serbia
- **Andrey Kaprin**, General Director, Federal State Budgetary Institution National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Chief Freelance Specialist Oncologist of the Ministry of Health of the Russian Federation **(online)**
- **Dmitry Kudlay**, Vice President for the Implementation of New Medical Technologies, Generium
- **Maria Makarova**, Doctor, Evogen, Russian Scientific Center for Radiology
- **Evgeny Shlyakhto**, General Director, Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
- **Tatyana Yakovleva**, First Deputy Head, Federal Medical-Biological Agency of the Russian Federation

Front row participants:

- **Timur Akhmerov**, General Director, BARS Group
- **Vladimir Ivanov**, Chief Executive Officer, Medgital
- **Sergey Kutsev**, Director of the Federal State Budgetary Scientific Institution "Medical Genetic Research Center named after A.I. Academician N.P. Bochkov"; Chief Freelance Specialist in Medical Genetics of the Ministry of Health of Russia
- **Alexey Lundup**, Director of the Scientific and Educational Resource Center for Cellular Technologies, Peoples' Friendship University of Russia

12:15–13:45

Pavilion G
conference hall G6

'Ensuring Drug Security' Russian Pharmaceutical Forum

Diabetes Mellitus: New Technologies at the Heart of Modern Therapy

Diabetes mellitus is one of the top three diseases worldwide that most often lead to disability and death. In Russia, the number of patients with diabetes has increased 2.5-fold over the past 20 years. The rapid development of new age medicine has opened up new opportunities in the diagnosis and treatment of this complex disease. The development of molecular genetic research has made it possible to improve diagnosis and use a personalized approach to treatment. The use of modern antidiabetic drugs helps prevent the development of acute complications and delay the development of

cardiovascular complications in type II diabetes. The development of drugs for immunotherapy of type I diabetes is underway. The emergence of new medical devices and digital technologies, including continuous glucose monitors, smart insulin pens, feedback-enabled insulin pumps, personal health assistants, mobile apps, telemedicine services, and AI systems have significant potential to improve the quality of care and treatment outcomes. Technologies such as bionic or artificial pancreas are expected in the future, with high hopes for the application of stem cell technologies. What innovative technologies for the treatment of diabetes are now available globally and are accessible in Russia? What promising developments in medicines and medical devices are taking place in our country? What technologies are most needed medically? How can we accelerate the introduction of digital technologies into the treatment of patients with diabetes? Which best practices from foreign countries can be used in our country?

Moderator:

- **Anastasia Stolkova**, First Deputy Chief Executive Officer for Development, Director of the Healthcare Directorate, Roscongress Foundation

Panellists:

- **Roman Dray**, Director of the Research Centre, GEROPHARM
- **Gagik Galstyan**, President, Russian Diabetes Association **(online)**
- **Vasily Generalov**, President, Regional Public Organization for Assistance to Patients with Epilepsy "Project" Don't Be Afraid"
- **Svetlana Kanevskaya**, Medical Director, Medscan Group
- **Sergei Lukyanov**, Rector, Pirogov Russian National Research Medical University
- **Natalia Mokrysheva**, Director, National Medical Research Center for Endocrinology Ministry of Health of the Russian Federation **(online)**
- **Elena Petryaykina**, Director, Russian Children's Clinical Hospital of the Russian National Research Medical University named after N.I. Pirogov

Front row participants:

- **Tamara Kozyreva**, Head, Help First Project
- **Bulat Valitov**, Doctor of the Russian Mini-Football Team for People with Diabetes; Head, Author's Online Diabetes School

12:15–13:45

Pavilion G
conference hall G7

'Ensuring Drug Security' Russian Pharmaceutical Forum

The Regulatory Response to Economic Sanctions: New Mechanisms Vital for Future Development of the Pharmaceutical Industry

Today, providing citizens with affordable, high-quality medicines in the context of the restrictive economic measures imposed on the Russian Federation is the key priority for the regulatory system for medicines. The Russian regulatory system, using the experience accumulated during the pandemic of making effective decisions to extremely tight deadlines, has demonstrated its resilience and readiness to respond quickly to global challenges, by showing how constructive and flexible it is and drawing on the principles of openness and cooperation. The creation of effective new legislation and the introduction of viable mechanisms of state support to ensure the future development of the national pharmaceutical industry are a fundamental ingredient in the industry's progress. To date, how effective are the conclusions of the interdepartmental commission in identifying medicines which are deficient, or at risk of becoming so? What results have been achieved in the area of state registration of medicines as well as that of the introduction of changes to documents in the registration dossier on an expedited basis? What solutions are needed for drug pricing issues in the context of the economic sanctions that have been imposed on the Russian Federation? What issues in the area of authorization require solutions in the Russian Federation in the context of the sanctions (moratoria in the pharmaceutical industry and other mechanisms)?

Moderator:

- **Dmitriy Galkin**, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation

Panellists:

- **Sergey Glagolev**, Deputy Minister of Health of the Russian Federation
- **Valentina Kosenko**, General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation
- **Timofey Nizhegorodtsev**, Deputy Head, Federal Antimonopoly Service of the Russian Federation **(online)**
- **Aleksandr Petrov**, Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection
- **Evgeniya Shapiro**, Director General, PSK Pharma

Front row participants:

- **Alla Samoylova**, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
- **Lyudmila Scherbakova**, Co-Founder, Chairman of the Board of Directors, Velpharm

14:30–16:00

Pavilion G
conference hall G4

'Ensuring Drug Security' Russian Pharmaceutical Forum

An Effective Strategy in Drug Provision

The demand for public financing of medicines and other health technologies always exceeds the resources available across health systems, regardless of the country's level of development. The problem dictates the need to choose the most effective medicines from a clinical and economic point of view within a limited budget. The Health Technology Assessment System (HTA) is a tool that allows to do it in a transparent and rational manner. This procedure is recognized as a tool for rational use of healthcare system funds in many countries. It has been a mandatory requirement for including medicines in the public financing system in the Russian Federation since 2014. The financial efficiency system by optimizing the choice of medicines needs to be constantly improved, taking into account the specifics of new technologies. Sharing best practices, knowledge, pooling the accumulated experience in this field contributes to more rational use of health systems. How to ensure the financial availability of drug therapy today? What are the limitations of the current HTA model for medicines? What further steps are required to improve current approaches to establishing restrictive lists of medicines? What are the approaches to HTA and procurement of innovative medicines? How should HTA and drug pricing be linked? Which areas of HTA should be prioritized for international cooperation and exchange of experiences?

Moderator:

- **Vitaliy Omelyanovskiy**, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation

Panellists:

- **Sara Al Dallal**, President, Emirates Health Economics Society (EHES) at Emirates Medical Association **(online)**
- **Anton Kugach**, Head of the Department of Organization of Drug Supply, Ministry of Health of the Republic of Belarus
- **Elena Maksimkina**, Director, "Federal Center for Planning and Regulation of Medical Supply Circulation" of the Ministry of Health of the Russian Federation
- **Oleg Malakhov**, Chairman of the Board of Directors, PRIMEKEY Group of Companies; member of the General Council, All-Russian public organization "Business Russia"

- **Nuria Musina**, Director of Development, Health Technology Assessment Association
- **Thi Thu Thuy Nguyen**, Dean, Pharmacy Faculty, Hong Bang International University
- **Melita Vujnovic**, Representative, World Health Organization Office in the Russian Federation

Front row participant:

- **Alima Almadiyeva**, Deputy Chairman of the Board, National Scientific Center for Health Development named after Salidat Kairbekova **(online)**

14:30–16:00

Pavilion G
conference hall G5

'Ensuring Drug Security' Russian Pharmaceutical Forum

Drug Security: International Cooperation and the Search for Joint Solutions

Current global challenges and the geopolitical situation dictate the need to build reliable partnerships with friendly countries, including to ensure drug security issues. It is necessary to create international platforms for dialogue between regulators, business, and professional communities to discuss harmonization of requirements for registration of medicines and certification of their production processes. Sharing experiences, removing excessive administrative barriers, and harmonizing requirements will facilitate the development and market launch of safe, effective, and high-quality medicines in the most resource-efficient way. What obstacles and challenges do pharmaceutical producers face when entering international markets? What are the specifics of drug registration and manufacturing certification requirements in the Russian Federation and a number of partner countries? What steps are needed to harmonize the approaches of our countries and improve access to medicines? Which medicines manufactured in Russia have a competitive export potential for international pharmaceutical markets?

Moderator:

- **Mikhail Khomich**, Managing Director for International Development, VEB.RF; Special Projects Director, Agency for Strategic Initiatives to Promote New Projects (ASI)

Panellists:

- **Hesa Sabah Al Doseri**, Chief, Health Facilities Regulation, National Health Regulatory Authority of the Kingdom of Bahrain (NHRA)
- **Sergey Glagolev**, Deputy Minister of Health of the Russian Federation
- **Valentina Kosenko**, General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation
- **Igor Obrubov**, General Director, Rusatom Healthcare
- **Martha Veronica Reyes Alvarez**, Minister of Health of the Republic of Nicaragua
- **Siddhartha Sankar Datta**, Regional Adviser of Vaccine-preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe
- **Tadzio Schilling**, Chief Executive Officer, Association of European Businesses (AEB)
- **Vladislav Shestakov**, Director, State Institute of Drugs and Good Practices
- **Olga Zhuravleva**, Deputy Director, Center for Examinations and Tests in Health Service

Front row participants:

- **Olesya Ledukhovskaya**, Founder, Asia Trade Group
- **Vadim Tarasov**, Director, Institute of Translational Medicine and Biotechnology Institute of Translational Medicine and Biotechnology, First Moscow State Medical University named after I.M. Sechenov
- **Victor Trukhin**, Director, Saint Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA of Russia

ENSURING DRUG SECURITY
RUSSIAN PHARMACEUTICAL FORUM

SPIEF'23
ST. PETERSBURG INTERNATIONAL ECONOMIC FORUM

ROSCONGRESS
Building Trust

14:30–16:00

Pavilion G
conference hall G6

'Ensuring Drug Security' Russian Pharmaceutical Forum

Priorities for Digital Transformation of the Pharmaceutical Market

Information technology has become firmly established in pharmacies, primarily in the areas of information sharing, the barcoding of medicines, and statistical data processing. The rules for prescribing medicines have changed, and prescriptions can be issued both in paper and electronic form. The drug flow monitoring system makes it possible to monitor the provision of medicines, to trace a medicine's path from manufacturer to pharmacy, thus guaranteeing its authenticity. Given the continuing problem of online sales of medicines which are prohibited or restricted, digitalization ensures the transparency and safety of both prescription and over-the-counter medicines. What are the benefits of developing a single digital network for all those involved in the pharmaceutical supply industry? Will the creation of a single digital network improve control over the availability of medicines in medical institutions and pharmacy chains? What are the risks of a full transition to an electronic prescription system? The laboratory information system: how, why, and for what?

Moderator:

- **Alla Samoylova**, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)

Panellists:

- **Dmitry Alkhazov**, Chief Executive Officer, Advanced Technologies Development Center (ATDC)
- **Dmitriy Galkin**, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation
- **Kirill Khromov**, Deputy Director General, E-APTEKA
- **Gennady Legostaev**
- **Viktor Nazarenko**, Member of the Board, Minister in Charge of Technical Regulation, Eurasian Economic Commission **(online)**
- **Aleksandr Petrov**, Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection
- **Pavel Pugachev**, Deputy Minister of Health of the Russian Federation
- **Artem Sokolov**, President, The Association of Internet Trade Companies

Front row participant:

- **Victor Dmitriev**, General Manager, Association of Russian Pharmaceutical Manufacturers

14:30–16:00

Pavilion H
conference hall H23
(2nd floor)

'Ensuring Drug Security' Russian Pharmaceutical Forum

Women in Pharmacy: Strategy, Dynamics and Trust

The pharmaceutical industry is the backbone of the provision of medicines to the population. It not only serves as the foundation for the national security of the country but also has a direct impact on public confidence in the healthcare system and the state as a whole. In recent years, the pharmaceutical industry has achieved significant advancements, demonstrating its ability to tackle various contemporary challenges, including COVID-19 and the evolving geopolitical landscape. A key driver of development in any industry is human capital. Women occupy diverse roles within the pharmaceutical industry, ranging from management positions to production. As leaders in this field, women contribute to the development of strategies, establish socially relevant priorities, and actively participate in research and production processes. In the production of medicines, more than 60% of employees are women. In the job market, the majority of job applicants are also women (about 89% of candidates in the industry). Women in the pharmaceutical industry are the absolute driving force behind internal

sector development. In which areas do women excel the most in the pharmaceutical industry today? What areas of growth and development do women see for the industry in the present context? Which innovative projects are they pursuing? Is there a necessity for dedicated platforms and initiatives to harness the potential of women within the industry?

Moderator:

- **Lyudmila Scherbakova**, Co-Founder, Chairman of the Board of Directors, Velpharm

Panellists:

- **Galina Karelova**, Deputy Chairman, Federation Council of the Federal Assembly of the Russian Federation
- **Diana Kobesova**, Deputy General Director for Pharmaceutical Business Development, Rusatom Healthcare
- **Antonina Melnichenko**, General Director, NIOPIK
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Anastasia Stolkova**, First Deputy Chief Executive Officer for Development, Director of the Healthcare Directorate, Roscongress Foundation
- **Tatyana Yakovleva**, First Deputy Head, Federal Medical-Biological Agency of the Russian Federation

Front row participants:

- **Irina Borovova**, President, Association of Cancer Patients "Zdravstvuy!"
- **Marina Rykova**, Strategic Marketing Director, GEROPHARM

16:30–18:00

Congress Centre
zone D, conference hall D1

'Ensuring Drug Security' Russian Pharmaceutical Forum

Plenary session

National Drug Policy: The Road to Russian Sovereignty

Today, in a time of geopolitical challenges, the role of national drug policy in the country's economic security strategy is becoming critically important. One of the priorities for government policy on the regulation of the use of medicines and medical devices is to produce drugs – primarily those from the list of vital and essential drugs (VED) and drugs of strategic importance – without being dependent on imports. Industry players are faced with the task of ensuring drug sovereignty in the country at all stages of production, from intermediates for the production of pharmaceutical substances to the full-scale roll-out of innovative import substitution of drugs in Russia using modern developments and cutting-edge scientific discoveries. Since destabilizing foreign economic pressure began to take effect, effective measures of state support for the Russian pharmaceutical industry were promptly devised, and today efforts should be focused not only on developing a roadmap for achieving sustainable national technological sovereignty, but also on strengthening the country's export potential, and increasing the presence of competitive, original Russian drugs on international markets. Which regulatory policies have helped the pharmaceutical industry to withstand the sanctions and ensure an uninterrupted supply of strategically important medicines? What kind of challenges does the pharmaceutical supply system face today, and which strategies can counter them? What government incentives can make it easier to achieve sovereignty in the timeframe required under the sanctions? In the current environment, how may we boost provision of groundbreaking drugs to the market and strengthen the export potential of the Russian pharmaceutical industry?

Welcome Remark:

- **Galina Karelova**, Deputy Chairman, Federation Council of the Federal Assembly of the Russian Federation

Moderator:

- **Evelina Zakamskaya**, Chief Editor, Doctor TV Channel

Panellists:

- **Sergey Glagolev**, Deputy Minister of Health of the Russian Federation
- **Aleksandr Petrov**, Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Alla Samoylova**, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
- **Tadzio Schilling**, Chief Executive Officer, Association of European Businesses (AEB)
- **Evgeniya Shapiro**, Director General, PSK Pharma
- **Evgeny Shlyakhto**, General Director, Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
- **Tatyana Yakovleva**, First Deputy Head, Federal Medical-Biological Agency of the Russian Federation